Publicacións nas que colabora con Alfredo García Layana (23)

2024

  1. Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration

    Ophthalmology Retina, Vol. 8, Núm. 4, pp. 350-359

2023

  1. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration

    Ophthalmology, Vol. 130, Núm. 6, pp. 588-597

  2. Análisis coste-utilidad del modelo de unidad de terapia intravítrea (UTI) frente a la administración tradicional de terapia intravítrea

    Archivos de la Sociedad Española de Oftalmologia, Vol. 98, Núm. 11, pp. 619-626

2022

  1. Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes

    Clinical and Experimental Ophthalmology, Vol. 50, Núm. 3, pp. 312-324

  2. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

    The Lancet, Vol. 399, Núm. 10326, pp. 729-740

  3. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

    The Lancet, Vol. 399, Núm. 10326, pp. 741-755

  4. Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry

    Ophthalmology Retina, Vol. 6, Núm. 11, pp. 1044-1053

  5. The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age-related macular degeneration long-term treated in real world

    Acta ophthalmologica, Vol. 100, Núm. 2, pp. e521-e531

2021

  1. A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration

    Nutrients, Vol. 13, Núm. 4

  2. Recommendations for ophthalmologic practice during the easing of COVID-19 control measures

    Acta Ophthalmologica, Vol. 99, Núm. 7, pp. e973-e983

2020

  1. Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study

    Acta Ophthalmologica, Vol. 98, Núm. 7, pp. e820-e829

2018

  1. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration

    Acta Ophthalmologica, Vol. 96, Núm. 2, pp. e201-e212

  2. Clinical decision-making when treating diabetic macular edema patients with dexamethasone intravitreal implants

    Ophthalmologica, Vol. 240, Núm. 2, pp. 61-72

2017

  1. Prevalence of Vitreoretinal Interface Abnormalities on Spectral-Domain OCT in Healthy Participants over 45 Years of Age

    Ophthalmology Retina

2015

  1. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration

    Journal of Ophthalmology, Vol. 2015

  2. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

    Drugs and Aging, Vol. 32, Núm. 10, pp. 797-807

2014

  1. A Delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration

    Journal of Ophthalmology, Vol. 2014

  2. Do nutritional supplements have a role in age macular degeneration prevention?

    Journal of Ophthalmology, Vol. 2014

2013

  1. Smoking and age-related macular degeneration: Review and update

    Journal of Ophthalmology, Vol. 2013

2011

  1. Myopic choroidal neovascularization

    Ophthalmology